Formycon Announces News on Development Portfolio
Preparation of FDA and EMA submission for FYB201 Positive conclusion of the pilot phase for FYB202 Preclinical study for…
Preparation of FDA and EMA submission for FYB201 Positive conclusion of the pilot phase for FYB202 Preclinical study for…
The biosimilars company Formycon from Martinsried near Munich (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has ended the 2017 finan…
. Clinical phase III study with FYB201 continues according to plan Half-year figures shaped by development expenses fo…
. Group sales grow significantly Development of FYB201 (ranibizumab) and FYB203 (aflibercept) biosimilar projects on…
Die Carl Zeiss Meditec AG hat im ersten Quartal 2016/17 den Wachstumskurs fortgesetzt: Der Umsatz stieg um 6,6 Prozent (…
Medical technology company Carl Zeiss Meditec AG closed financial year 2013/2014 with a slight growth in revenue from €…
Facing a slight downturn in the overall market, Medical technology provider Carl Zeiss Meditec AG raised its revenue by…
Irrespective of the difficult underlying global economic conditions, Carl Zeiss Meditec AG closed the first quarter of f…
Medical technology provider Carl Zeiss Meditec AG continued on its growth course in the third quarter of financial year…
Medical technology provider Carl Zeiss Meditec generated growth of 14.8 percent in the first six months of financial yea…